Benign Prostatic Hyperplasia Clinical Trial
— Prost-EMBOLOfficial title:
Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.
Background: Patients with indwelling urinary catheter for chronic retention due to
obstructive BPH refractory to medical therapy are candidates for prostatectomy still
considered as the gold standard of treatment. Urinary tract infection, strictures,
postoperative pain, incontinence, sexual dysfunction, anesthesiologist risk and blood loss
are complications associated with surgery. Minimally invasive treatments were originally
conceived as an attempt to offer equivalent efficacy without the burden and risk of
operative morbidity. Recently, it was suggested that prostatic arterial embolization (PAE)
to treat BPH might follow uterine artery embolization for uterine leiomyomas. Animal studies
in pigs and dogs have shown that PAE is safe and can induce prostatic volume reduction. The
first report of this technique in the management of BPH in humans was by DeMeritt et al, who
reported a single case of BPH with obstructive symptoms and blood loss refractory to other
treatments that was successfully managed by PAE with polyvinyl alcohol (PVA) particles.
Objective : We investigate whether PAE might be a feasible procedure as an alternative
treatment option to treat urinary retention due to obstructive BPH. The primary objective is
to evaluate the success rate of procedure defined when selective prostatic arterial
catheterization and embolization were achieve and patients can be able to urinate after
their urinary catheter has been removed.
Patients and methods : A monocentric prospective study is undertaken in 25 patients aged
50-85 years who present with indwelling urinary catheter due to obstructive BPH refractory
to medical treatment with a clinical indication for surgery who agreed to undergo PAE. The
study is approved by the hospital ethical committee and an informed consent form for PAE as
an alternative treatment is signed by all participants.
Statistical analysis : The sample size has been calculated in order to have an estimated
probability of success (corresponding of primary objective) of 50% (worst case) with 95%
confidence intervals of 30 to 70. The two-sample t-test (and Wilcoxon rank-sum test) is used
to compare the mean changes of the variables from baseline to 10, 30 and 90 days. Finally,
the Chi-square test is used to test for adverse events at the end of follow-up. P ≤ 0.05 is
indicative of statistically significant.
Status | Terminated |
Enrollment | 2 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patients with a urinary retention due to obstructive benign prostatic hyperplasia (BPH) confirmed by endoscopy, - Patients aged 50-85 years, - Patients with indwelling urinary catheter for at least 1 month, - Patients with at least one failure of a trial without catheter despite alpha-blocker treatment for at least 72 hours, - Patients informed about alternative treatment (transurethral resection of the prostate, laser prostatectomy, prostatic adenomectomy), - Patients signed an informed consent form. Exclusion Criteria: - Prostate cancer (evaluated by PSA, physical examination, in all patients and by prostatic biopsy in suspicious cases). - History of relevant neurological disease (e.g. multiple sclerosis, spinal cord injury, parkinson's disease). - Patients who have on urodynamic investigation evidence of an atonic bladder. - Urethral stricture - Chronic persistent local pathology that may cause urinary symptoms (e.g. interstitial cystitis, tumor, bladder stone). - Renal insufficiency stade 3 or 4 (creatinine clearance < 35 mL/min) - Any allergy or contraindication to ciprofloxacin or drugs used in this protocole (xylocaine, Atarax, paracetamol, and nonsteroidal anti-inflammatory drug) - Any allergy to intravenous contrast agent or iodine - Thyrotoxicosis - Concomitant use of tizanidine - Patients participating to another research protocol |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Rouen University Hospital | Rouen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural Success | Procedural success was defined as cessation of extravasation and/or occlusion of the targeted vessel on postembolization arteriography. Voiding diary : mictirution volume and postvoid residual volume measurements by ultrasonography |
Day 1 | Yes |
Secondary | success of the procedure : ability to urinate after their catheter | Ablation of Indwelling Urinary Catheter | Day 10 | Yes |
Secondary | success of the procedure : ability to urinate after their catheter | Ablation of Indwelling Urinary Catheter | Day 90 | Yes |
Secondary | success of the procedure : ability to urinate after their catheter | Ablation of Indwelling Urinary Catheter | Day 30 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT04853914 -
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
|
N/A |